Incyte boosts annual sales forecast of blood cancer drug after strong quarter

Core Insights - Incyte Corp has raised its annual sales forecast for Jakafi, a blood cancer treatment, due to strong demand that exceeded Wall Street estimates for the third quarter [1] Financial Performance - The company reported robust demand for Jakafi, leading to a positive financial outlook [1] - The updated sales forecast reflects confidence in the drug's market performance [1]